CPC C07K 16/244 (2013.01) [A61K 39/395 (2013.01); A61K 47/6845 (2017.08); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] | 26 Claims |
1. A pharmaceutical composition comprising an excipient and an antigen-binding molecule, the antigen-binding molecule comprising:
(a) a first polypeptide comprising, in an N- to C-terminal orientation:
(i) a first Fc domain; and
(ii) a first linker;
(iii) a first VH domain; and
(iv) a first CH1 domain,
wherein the first polypeptide lacks a binding domain N-terminal to the first Fc domain;
(b) a second polypeptide comprising, in an N- to C-terminal orientation:
(i) a second Fc domain;
(ii) a second linker;
(iii) a second VH domain; and
(iv) a second CH1 domain,
wherein the second polypeptide lacks a binding domain N-terminal to the second Fc domain;
(c) a third polypeptide associated with the first polypeptide comprising, in an N-to-C terminal orientation, a first VL domain and a first CL domain, wherein the first VL domain and the first CL domain are associated with the first VH domain and the first CH1 domain to form a first Fab domain; and
(d) a fourth polypeptide associated with the second polypeptide comprising, in an N-to-C terminal orientation, a second VL domain and a second CL domain, wherein the second VL domain and the second CL domain are associated with the second VH domain and the second CH1 domain to form a second Fab domain.
|